natgillin/translations-raw huggingface dataset:
Humira does not contain preservatives.
Zdravilo Humira ne vsebuje konzervanzov.
Humira has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see Section 5.1) and to improve physical function.
Z rentgenskim slikanjem je bilo dokazano, da zdravilo Humira upočasni hitrost napredovanja prizadetosti perifernih sklepov pri bolnikih s poliartikularno, simetrično podvrsto bolezni (glejte poglavje 5.1) in izboljša telesno funkcijo.
Humira has been shown to slow down the damage to the cartilage and bone of the joints caused by the disease and to improve physical function.
Zdravilo Humira dokazano upočasni napredovanje prizadetosti sklepnih hrustancev in kosti, ki jo povzroči bolezen, in izboljša telesno delovanje.
Humira has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic arthritis patients taking Humira as monotherapy and those taking concomitant methotrexate.
Zdravilo Humira so raziskali pri bolnikih z revmatoidnim artritisom, poliartikularnim juvenilnim idiopatskim artritisom in revmatoidnim artritisom, ki so zdravilo Humira jemali v monoterapiji, kot pri tistih, ki so jo jemali hkrati z metotreksatom.
Humira has not been studied in patients aged less than 2 years.
Raziskave z zdravilom Humira pri bolnikih mlajših od 2 let niso bile izvedene.
Humira has not been studied in patients aged less than 2 years.
Raziskave z zdravilom Humira pri bolnikih, starih manj kot 2 leti, niso bile izvedene.
Humira has not been studied in patients aged less than 2 years.
Študije z zdravilom Humira pri bolnikih, starih manj kot 2 leti, niso bile izvedene.
Humira has not been studied in patients with hepatic or renal impairment
Zdravila Humira niso proučili pri bolnikih z okvaro jeter ali ledvic.
Humira has not been studied in these patient populations.
Zdravila Humira pri tej populaciji bolnikov niso preučili.
Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).
Zdravilo Humira je v kombinaciji z metotreksatom indicirano za zdravljenje aktivnega poliartikularnega juvenilnega idiopatskega artritisa pri bolnikih od 2.leta starosti, ki se ne odzovejo ustrezno na eno ali več imunomodulirajočih antirevmatičnih zdravil.
Humira is a liquid that is clear and colourless.
Zdravilo Humira je bistra in brezbarvna tekočina.
Humira is a medicine that contains the active substance adalimumab.
Humira je zdravilo, ki vsebuje zdravilno učinkovino adalimumab.
Humira is administered by injection under the skin (by subcutaneous injection).
Zdravilo Humira se injicira pod kožo (subkutana uporaba).
Humira is administered by subcutaneous injection.
Zdravilo Humira se uporablja kot subkutana injekcija.
Humira is also available as a pre-filled syringe or a pre-filled pen.
Zdravilo Humira je na voljo tudi kot napolnjena injekcijska brizga ali napolnjen injekcijski peresnik.
Humira is also used to treat severe plaque psoriasis in children and adolescents aged 4 to 17 years for whom topical therapy and phototherapies have either not worked very well or are not suitable.
Zdravilo Humira se uporablja tudi za zdravljenje hude luskavice v plakih pri otrocih in mladostnikih, starih od 4 do 17 let, pri katerih lokalno zdravljenje in zdravljenja s svetlobo nista dovolj dobro delovala ali pa nista primerna.
Humira is also used to treat the following patients who have not responded adequately to other treatments or cannot use them:
Zdravilo Humira se uporablja za zdravljenje naslednjih bolnikov, ki se niso ustrezno odzvali na druga zdravljenja ali jih ne morejo prejemati:
Humira is available as a vial, a pre-filled syringe and a pre-filled pen.
Zdravilo Humira je na voljo v viali, napolnjeni injekcijski brizgi in napolnjenem injekcijskem peresniku.
Humira is available as a vial, a pre-filled syringe, and a pre-filled pen.
Zdravilo Humira je na voljo v viali, napolnjeni injekcijski brizgi in napolnjenem injekcijskem peresniku.
Humira is available as a vial, a pre-filled syringeand a pre-filled pen.
Zdravilo Humira je na voljo v viali, napolnjeni injekcijski brizgi in napolnjenem injekcijskem peresniku.
Humira is contraindicated in moderate to severe heart failure (see section 4.3).
Pri bolnikih z zmernim ali hudim srčnim popuščanjem je zdravilo Humira kontraindicirana (glejte poglavje 4.3).
Humira is contraindicated in moderate to severe heart failure (see section 4.3).
Pri bolnikih z zmernim ali hudim srčnim popuščanjem je zdravilo Humira kontraindicirano (glejte poglavje 4.3).
Humira is given as an injection under the skin.
Zdravilo Humira se daje z injiciranjem pod kožo.
Humira is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).
Zdravilo Humira je indicirano za zdravljenje aktivnega artritisa, povezanega z entezitisom pri bolnikih, starih 6 let in več, ki so se neustrezno odzvali ali so intolerantni za običajno zdravljenje (glejte poglavje 5.1).
Humira is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.
Zdravilo Humira je indicirano za zdravljenje aktivne zmerne do hude oblike hidradenitis suppurativa (acne inversa) pri odraslih bolnikih, ki se ne odzovejo zadovoljivo na konvencionalno HS zdravljenje.
Humira is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.
Zdravilo Humira je indicirano za zdravljenje hudega aktivnega ankilozirajočega spondilitisa pri odraslih, ki se na konvencionalno terapijo ne odzovejo ustrezno.
Humira is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and / or MRI, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs.
Zdravilo Humira je indicirano za zdravljenje odraslih s hudim aksialnim spondiloartritisom brez radiografskega dokaza za AS, toda z objektivnimi znaki vnetja s povišanimi CRP in/ali MRI, ki so nezadostno reagirali na ali ne prenašajo nesteroidnih protivnetnih zdravil.
Humira is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.
Zdravilo Humira je indicirano za zdravljenje zmerno do hudo aktivne Crohnove bolezni pri pediatričnih bolnikih (od 6.leta starosti), ki se ne odzovejo zadovoljivo na konvencionalno zdravljenje, vključno s primarno prehransko terapijo in kortikosteroidom in/ali imunomodulatorjem, ali pri tistih, ki imajo intoleranco ali kontraindikacije za tako zdravljenje.
Humira is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.
Zdravilo Humira je indicirano za zdravljenje neinfekcijskega intermediarnega, posteriornega uveitisa in panuveitisa pri odraslih bolnikih, ki se niso zadostno odzvali na zdravljenje s kortikosteroidi, pri bolnikih s potrebo po zmanjšani uporabi kortikosteroidov ali pri bolnikih, pri katerih je zdravljenje s kortikosteroidi neprimerno.
Humira is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
Zdravilo Humira je indicirano za zdravljenje zmerneo do hudo aktivne Crohnove bolezni pri odraslih bolnikih, ki se ne odzovejo na popoln in ustrezen ciklus zdravljenja s kortikosteroidom in/ali imunosupresivom, ali pa takšnega zdravljenja ne prenesejo oz. imajo zanj medicinske kontraindikacije.
Humira is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
Zdravilo Humira je indicirano za zdravljenje zmerno do hudo aktivne Crohnove bolezni pri odraslih bolnikih, ki se ne odzovejo na popoln in ustrezen ciklus zdravljenja s kortikosteroidom in/ali imunosupresivom, ali pa takšnega zdravljenja ne prenesejo oz. imajo zanj medicinske kontraindikacije.
Humira is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6- mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
Zdravilo Humira je indicirano za zdravljenje zmerno do močno aktivnega ulceroznega kolitisa pri odraslih bolnikih, ki se ne odzovejo zadostno na običajno zdravljenje, na primer na kortikosteroide in 6-merkaptopurin (6-MP) ali azatioprin (AZA), ali pa takšnega zdravljenja ne prenesejo oz. imajo zanj medicinske kontraindikacije.
Humira is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6- mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
Zdravilo Humira je indicirano za zdravljenje zmerno do močno aktivnega ulceroznega kolitisa pri odraslih bolnikih, ki so se ne odzovejo zadostno na običajno zdravljenje, na primer na kortikosteroide in 6-merkaptopurin (6-MP) ali azatioprin (AZA), ali pa takšnega zdravljenja ne prenesejo oz. imajo zanj medicinske kontraindikacije.
Humira is intended for treatment of polyarticular juvenile idiopathic arthritis in children 2-17 years, enthesitis-related arthritis in children 6-17 years ,Crohn’s disease in children 6-17 years and plaque psoriasis in children from 4-17 years.
Zdravilo Humira je namenjeno za zdravljenje poliartikularnega juvenilnega idiopatskega artritisa pri otrocih, starih 2-17 let, artritisa, povezanega z entezitisom pri otrocih, starih 6-17 let, Crohnove bolezni pri otrocih, starih 6-17 let in luskavice (psoriaze) v plakih pri otrocih, starih od 4-17 let.
Humira is intended for treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis- related arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis and non-infectious uveitis affecting the back of the eye.
Zdravilo Humira je namenjeno za zdravljenje revmatoidnega artritisa, poliartikularnega juvenilnega idiopatskega artritisa, artritisa, povezanega z entezitisom, ankilozirajočega spondilitisa, aksialnega spondiloartritisa brez radiografskega dokaza za ankilozirajoči spondilitis, psoriatičnega artritisa, luskavice (psoriaze), hidradenitis suppurativa, Crohnove bolezni, ulceroznega kolitisa in neinfekcijskega uveitisa, ki prizadene zadnji del očesa.
Humira is intended for treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis and non-infectious uveitis affecting the back of the eye.
Zdravilo Humira je namenjeno za zdravljenje revmatoidnega artritisa, poliartikularnega juvenilnega idiopatskega artritisa, artritisa, povezanega z entezitisom, ankilozirajočega spondilitisa, aksialnega spondiloartritisa brez radiografskega dokaza za ankilozirajoči spondilitis, psoriatičnega artritisa, luskavice (psoriaze), hidradenitis suppurativa, Crohnove bolezni, ulceroznega kolitisa in neinfekcijskega uveitisa, ki prizadene zadnji del očesa.
Humira is used to treat
Zdravilo Humira se uporablja za zdravljenje:
Humira is used to treat adults with moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin) who need systemic therapy (a treatment given by mouth or injection).
Zdravilo Humira se uporablja za zdravljenje odraslih z zmerno do hudo psoriazo s plaki (bolezen, ki povzroča rdeče, luskaste zaplate na koži), ki potrebujejo sistemsko zdravljenje (peroralno ali v obliki injekcije).
Humira is used to treat adults with non-infectious uveitis with inflammation affecting the back of the eye.
Zdravilo Humira se uporablja za zdravljenje pri odraslih z neinfekcijskim uveitisom, tj. vnetjem, ki prizadene zadnji del očesa.
Humira is used to treat Crohn’s disease in adults and children aged 6 to 17 years.
Zdravilo Humira se uporablja za zdravljenje Crohnove bolezni pri odraslih in otrocih, starih 6 do 17 let.
Humira is used to treat hidradenitis suppurativa in adults.
Zdravilo Humira se uporablja za zdravljenje hidradenitis suppurativa pri odraslih.
Humira is used to treat moderate to severe Crohn’s disease in adults and moderate to severe Crohn’s disease in children and adolescents from 6 years of age
Zdravilo Humira se uporablja za zdravljenje zmerne do hude Crohnove bolezni pri odraslih in zmerne do hude Crohnove bolezni pri otrocih od 6. leta starosti
Humira is used to treat moderate to severe hidradenitis suppurativa in adults.
Zdravilo Humira se uporablja za zdravljenje zmernega do hudega hidradenitis suppurativa pri odraslih.
Humira is used to treat moderate to severe plaque psoriasis in adults.
Zdravilo Humira se uporablja za zdravljenje luskavice pri odraslih.
Humira is used to treat moderate to severe plaque psoriasis in adults.
Zdravilo Humira se uporablja za zdravljenje zmerne do hude luskavice pri odraslih.
Humira is used to treat moderate to severe ulcerative colitis in adults.
Zdravilo Humira se uporablja za zdravljenje zmernega do hudega ulceroznega kolitisa pri odraslih.
Humira is used to treat polyarticular juvenile idiopathic arthritis in children and adolescents aged 2 to 17 years and enthesitis-related arthritis in children and adolescents aged 6 to 17 years.
Zdravilo Humira se uporablja za zdravljenje poliartikularnega juvenilnega idiopatskega artritisa pri otrocih in mladostnikih, starih 2 do 17 let in artritisa, povezanega z entezitisom pri otrocih in mladostnikih starih od 6 do 17 let.
Humira is used to treat severe plaque psoriasis in children and adolescents aged 4 to 17 years in whom topical therapy and phototherapies have either not worked very well or are not suitable.
Zdravilo Humira se uporablja za zdravljenje hude luskavice v plakih pri otrocih in mladostnikih, starih od 4 do 17 let, pri katerih lokalno zdravljenje in zdravljenja s svetlobo nista dovolj dobro delovala ali pa nista primerna.
Humira may have a minor influence on the ability to drive and use machines.
Zdravilo Humira ima lahko blag vpliv na sposobnost vožnje in upravljanja s stroji.
Humira may have a minor influence on the ability to drive, cycle or use machines.
Zdravilo Humira ima lahko blag vpliv na sposobnost vožnje, kolesarjenja ali upravljanja s stroji.
Humira may have a minor influence on your ability to drive, cycle or use machines.
Zdravilo Humira ima lahko blag vpliv na sposobnost vožnje, kolesarjenja ali upravljanja s stroji.
Humira may have a small effect on your ability to drive, cycle or use machines.
Zdravilo Humira ima lahko majhen vpliv na sposobnost vožnje, kolesarjenja ali upravljanja s stroji.
Humira must not be used in patients with active tuberculosis, other severe infections, or moderate to severe heart failure (an inability of the heart to pump enough blood around the body).
Zdravilo Humira se ne sme uporabljati pri bolnikih z aktivno tuberkulozo, drugimi hudimi okužbami ali zmernim do hudim srčnim popuščanjem (stanjem, pri katerem srce ne zmore črpati dovolj krvi po telesu).
Humira N=151
Humira N=91
Humira n=274 (95% confidence interval)
Zdravilo Humira n = 274 (95 % interval zaupanja)
Humira n=274 (95% confidence interval)
Zdravilo Humira n = 274 (95% interval zaupanja)
Humira Pre-filled Pen
Zdravilo Humira napolnjen peresnik
Humira showed statistically significantly greater improvement in the HAQ-S total score and the SF-36 Physical Component Score (PCS) from baseline to week 12 compared to placebo.
Zdravilo Humira je pokazalo statistično večje izboljšanje skupnega števila točk v HAQ-S vprašalniku in točk v telesni komponenti (Physical Component Score (PCS)) v SF-36 vprašalniku od začetka do 12.tedna v primerjavi s placebom.
Humira showed statistically significantly greater improvement in the HAQ-S total score and the SF-36 Physical Component Score (PCS) from baseline to week 12 compared to placebo.
Zdravilo Humira je pokazalo statistično večje izboljšanje skupnega števila točk v HAQ-S vprašalniku in točk v telesno komponenti (Physical Component Score (PCS)) v SF-36 vprašalniku od začetka do 12.tedna v primerjavi s placebom.
Humira treated patients had significantly greater improvement at Week 12 which was maintained through Week 24 in both the SF36 and Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL).
Bolniki, ki so dobivali zdravilo Humira, so imeli po 12 tednih značilno večje izboljšanje (ki se je ohranilo do 24. tedna) SF36 in ASQoL (Vprašalnik o kakovosti življenja pri ankilozirajočem spondilitisu – Ankylosing Spondylitis Quality of Life Questionnaire).
Humira treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of conditons for which Humira is indicated.
Zdravljenje z zdravilom Humira mora uvesti in nadzorovati zdravnik specialist, izkušen v diagnosticiranju in zdravljenju bolezni, za katere je zdravilo Humira indicirano.
Humira was assessed in a multicenter, randomised, double-blind clinical trial designed to evaluate the efficacy and safety of induction and maintenance treatment with doses dependent on body weight (< 40 kg or ≥ 40 kg) in 192 paediatric subjects between the ages of 6 and 17 (inclusive) years, with moderate to severe Crohn´s disease (CD) defined as Paediatric Crohn's Disease Activity Index (PCDAI) score > 30.
Zdravilo Humira je bilo ocenjeno v multicentrični, randomizirani, dvojno slepi klinični študiji, ki je bila zasnovana za oceno učinkovitosti in varnosti uvodnega in vzdrževalnega zdravljenja z odmerki, odvisnimi od telesne mase (< 40 mg ali ≥ 40 mg) pri 192 pediatričnih bolnikih med 6. in 17. (vključno) letom starosti, z zmerno do hudo Crohnovo boleznijo (CD) definirano kot vrednost indeksa Pediatric Crohn’s Disease Activity Index (PCDAI) > 30.
Humira was evaluated in over 3000 patients in all rheumatoid arthritis clinical trials.
V vseh kliničnih preskušanjih revmatoidnega artritisa so zdravilo Humira ocenili pri več kot 3000 bolnikih.
Humira was studied in 9,506 patients in pivotal controlled and open label trials for up to 60 months or more.
Zdravilo Humira so raziskali pri 9506 bolnikih v kontroliranihin odprtih preskušanjih, ki podpirajo vlogo za pridobitev dovoljenja za promet in so trajala do 60 mesecev ali več.
Humira with food and drink
Zdravilo Humira skupaj s hrano in pijačo
Humira works by reducing this inflammation.
Zdravilo Humira deluje tako, da zmanjša tako vnetje.
Humira, 40 mg every other week, was studied in patients with moderately to severely active psoriatic arthritis in two placebo-controlled studies, PsA I and II.
Uporabo zdravila Humira 40 mg vsak drugi teden so pri bolnikih z zmernim do zelo aktivnim psoriatičnim artritisom proučili v dveh s placebom kontroliranih študijah, študijah pri psoriatičnem artritisu I in II.
Humira, 40 mg every other week, was studied in patients with moderately to severely active psoriatic arthritis in two placebo-controlled studies, PsA studies I and II.
Uporabo zdravila Humira 40 mg vsak drugi teden so pri bolnikih z zmernim do zelo aktivnim psoriatičnim artritisom proučili v dveh s placebom kontroliranih študijah, študijah pri psoriatičnem artritisu I in II.
Humira, when used as directed, has been shown in clinical trials to be effective at reducing important symptoms of each of the conditions for which it has been recommended.
Zdravilo Humira se je v kliničnih preskušanjih ob pravilni uporabi izkazalo za učinkovito pri zmanjševanju pomembnih simptomov pri vsaki od bolezni, za katero se njegova uporaba priporoča.
Humira/methotrexate patients demonstrated significantly less radiographic progression than patients receiving methotrexate alone at 6 and 12 months (see Table 4).
Pri bolnikih, ki so dobivali zdravilo Humira in metotreksat, je bilo po 6 in 12 mesecih (glejte preglednico 4) statistično značilno manj rentgenografskih znakov napredovanja kot pri bolnikih, ki so dobivali samo metotreksat.
Humira/methotrexate patients demonstrated significantly less radiographic progression than patients receiving methotrexate alone at 6 and 12 months (see Table 4).
Pri bolnikih, ki so dobivalizdravilo Humira in metotreksat, je bilo po 6 in 12 mesecih (glejte preglednico 4) statistično značilno manj rentgenografskih znakov napredovanja kot pri bolnikih, ki so dobivali samo metotreksat.
Humira/methotrexate patients demonstrated significantly less radiographic progression than patients receiving methotrexate alone at 6 and 12 months (see Table 6).
Pri bolnikih, ki so dobivali zdravilo Humira in metotreksat, je bilo po 6 in 12 mesecih (glejte preglednico 6) statistično značilno manj rentgenografskih znakov napredovanja kot pri bolnikih, ki so dobivali samo metotreksat.
Humira/methotrexate patients demonstrated significantly less radiographic progression than patients receiving methotrexate alone at 6 and 12 months (see Table 6).
Pri bolnikih, ki so dobivalizdravilo Humira in metotreksat, je bilo po 6 in 12 mesecih (glejte preglednico 6) statistično značilno manj rentgenografskih znakov napredovanja kot pri bolnikih, ki so dobivali samo metotreksat.
Humira/methotrexate patients demonstrated significantly less radiographic progression than patients receiving methotrexate alone at 6 and 12 months (see Table 8).
Pri bolnikih, ki so dobivali zdravilo Humira in metotreksat, je bilo po 6 in 12 mesecih (glejte preglednico 8) statistično značilno manj rentgenografskih znakov napredovanja kot pri bolnikih, ki so dobivali samo metotreksat.
Humira/MTX 40 mg every other week
Zdravilo Humira/MTX 40 mg vsak drugi teden
Humira/MTX n=268
Zdravilo Humira/MT X
Humira/MTX n=268 (95%
Zdravilo Humira/MT X
HUNGARIA
MADŽARSKA
Hungary (Headquarters: 4042 Debrecen, Pallagi út 13)
Madžarska (sedež: 4042 Debrecen, Pallagi út 13)
Hungary/ Magyarország
Madžarska/Magyarország
hunger
labše celjenje,
hunger
lakota
hunger
lakoto,
hunger disease of the gallbladder
lakota bolezen žolčnika
hunger,
lakoto,
Hunger, Pyrexia
Lakota, pireksija
Hycamtin 0.25 mg capsules are white to yellowish white and imprinted with ‘Hycamtin’ and ‘0.25 mg’.
0,25-mg kapsule Hycamtin so bele do rumenkasto bele in označene s ‘Hycamtin’ in ‘0.25 mg’.
Hycamtin 1 mg capsules are pink and imprinted with ‘Hycamtin’ and ‘1 mg’.
1-mg kapsule Hycamtin so rožnate barve in označene s ‘Hycamtin’ in ‘1 mg’.
HYCAMTIN 1 mg is available in cartons containing 1 vial and 5 vials.
HYCAMTIN 1 mg je na voljo v škatlah z 1 vialo in 5 vialami.
HYCAMTIN 1 mg is supplied in 5 ml type I flint glass vials, together with 13 mm grey butyl rubber stoppers and 13 mm aluminium seals with plastic flip-off caps.
HYCAMTIN 1 mg je na voljo v 5-ml vialah iz kristalnega stekla (tip I), ki so opremljene s 13-mm sivimi zamaški iz butilne gume, zapečatene s 13-mm aluminijasto zaporko s plastičnim pokrovom (flip-off).